We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
SCENESSE (Clinuvel Pharmaceuticals Ltd)
Product name
SCENESSE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
144 working days (150)
Active ingredients
afamelanotide acetate
Registration type
NCE/NBE
Indication
SCENESSE (implant) is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.